[Candidiasis in AIDS patients] NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[Candidiasis in AIDS patients]

Rev Soc Bras Med Trop. 1992 Jul-Sep;25(3):165-9. Unique Identifier : AIDSLINE MED/93391691
Campos CE; Igreja RP; Campos EP; Depto. de Microbiologia e Imunologia, Universidade Estadual; Paulista, Botucatu, SP, Brasil.

Abstract: A total of 35 in patients admitted at Emilio Ribas Hospital--Sao Paulo, Brazil, with digestive candidiasis and AIDS clinical diagnostic were evaluated 10 month later, being 29 male and 6 female; white outnumbering black with age ranged from 30 to 50 years old. Agar Sabouraud culture and tube germinative tests identified 28 (80%) Candida albicans out 35 strains. Minimum inhibitory concentration (MIC) 50% was against azoles (ketoconazole = 2.2 micrograms/ml; itraconazole = 21.0 micrograms/ml and fluconazole = 19.0 micrograms/ml); polyenes (nystatin = 50.0 micrograms/ml and amphotericin B = 0.12 micrograms/ml) and 5 fluorocytosine = 1.6 micrograms/ml. Siegel tests showed significant Candida albicans proportions in strains isolated from 35 AIDS patients. There was no significant relation between AMB doses and early or late death. Conclusions: candidiasis in AIDS patients showed high MIC 50% to azoles and nystatin and significant Candida albicans proportion in all strains isolated from AIDS patients. Previous amphotericin B therapy had no influence in early or late death in 30 patients. Previous therapy possibly explained MIC 50% increases in Candida strains.
Keywords: Adult Antifungal Agents/ADMINISTRATION & DOSAGE AIDS-Related Opportunistic Infections/*DIAGNOSIS/DRUG THERAPY/ MICROBIOLOGY/MORTALITY Brazil/EPIDEMIOLOGY Candida albicans/DRUG EFFECTS/ISOLATION & PURIF Candidiasis, Oral/*DIAGNOSIS/DRUG THERAPY/MICROBIOLOGY/MORTALITY Chi-Square Distribution English Abstract Female Human Male Microbial Sensitivity Tests JOURNAL ARTICLEKWDadultantifungalagents/administration&dosageaids-relatedopportunisticinfections/KWDdiagnosis/drugtherapy/microbiology/mortalitybrazil/epidemiologycandidaalbicans/drugeffects/isolation&purifcandidiasis,oral/KWDdiagnosis/drugtherapy/microbiology/mortalitychi-squaredistributionenglishabstractfemalehumanmalemicrobialsensitivitytestsjournalarticle
931230
M93C0773

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .